Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis

Shen, Jinze; Liang, Chenhao; Su, Xinming; Wang, Qurui; Ke, Yufei; Fang, Jie; Zhang, Dayong; Duan, Shiwei

doi:10.1186/s40364-022-00419-8

Biomarker Research

Table 1 General downregulated expression of miR-637 in different cancers

From: Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis

Systems	Diseases	Expression	Level	Normal Group	Disease Group	Ref
Nervous	GBM/LGG	downregulated	tissue	normal brain tissues from 15 healthy people	27 snap-frozen glioma tissues from 27 glioma patients	[9]
	GBM/LGG	downregulated	tissue	adjacent normal brain tissues from 40 gliomas patients	glioma tissues from 40 gliomas patients	[8]
	GBM	downregulated	tissue	28 non-neoplastic brain tissue samples	primary GBM surgical specimens from 161 GBM patients	[11]
	GBM	downregulated	tissue	normal human astrocytes from healthy people	GBM tissues from 71 GBM patients	[10]
Endocrine	PTC	downregulated	cell	Nthy-ori 3–1	TPC-1, CGTH-W3, IHH-4, HTH83, and SW579	[12, 13]
		downregulated	tissue	adjacent normal tissues	PTC tissues from 54 PTC patients	[12]
		downregulated	tissue	homologous adjacent normal tissues	paraffin-embedded tumor tissues from PTC patients	[13]
Respiratory	NSCLC	downregulated	tissue	adjacent normal tissues	NSCLC tissues from 74 male and 49 female NSCLC patients	[14]
Digestive	GC	downregulated	tissue	adjacent normal tissues	GC tissues from 30 GC patients	[15]
		downregulated	tissue	adjacent normal tissues	GC tissues from 30 male and 28 female	[16]
		downregulated	cell	GES-1	BGC- 823, CRL-5822, SGC-7901, and AGS	[17]
		downregulated	tissue	adjacent normal tissues	GC tissues from 10 patients	[17]
	HCC	downregulated	tissue	10 of non-neoplastic and non-cirrhotic liver tissue	HCC tissue from 15 patients	[19]
		downregulated	tissue	normal liver tissues	HCC specimens from 52 patients	[21]
		downregulated	cell	MIHA	HepG2, Hep3B, Bel7404, and Huh-7	[21]
		downregulated	tissue	adjacent normal tissue samples	HCC tissue samples from 63 patients	[18]
		downregulated	cell	THLE-3	Huh7, HepG2, MHCC-97H, and Hep3B	[18]
		downregulated	tissue	adjacent normal tissues	HCC tissues from 46 patients	[20]
	CRC	downregulated	tissue	adjacent normal tissues	CRC tissues from 50 CRC patients	[22]
	PDAC	downregulated	tissue	adjacent non-neoplastic tissues	PDAC tissues from 25 PDAC patients	[23]
	PDAC	downregulated	cell	HPDE	SW1990, BxPC-3, and Capan-2	[23]
	CHOL	downregulated	cell	H69	TFK-1, SNU-869, SSP-25, RBE, HuCCT1, and HuH28	[36]
		downregulated	serum	serum from healthy people	serum from 40 CHOL patients	[39]
		downregulated	tissue	adjacent tissues	CHOL tissues from 41 CHOL patients	[24]
	OSCC	downregulated	cell	NOK	OSCC-15, Tca8113, SCC-9, SCC-25, and HSC-2	[35]
	OSCC	downregulated	tissue	adjacent normal tissues	OSCC tissurs from 51 OSCC patients	[25]
Urinary	PCa	downregulated	tissue	matched adjacent normal tissues	PCa tissues from 65 PCa patients	[26]
Urinary	ccRCC	upregulated	tissue	matched adjacent normal renal tissues	ccRCC tissues from 40 ccRCC patients	[40]
Reproductive	OC	downregulated	tissue	adjacent normal tissues	10 OC tissue from OC patients	[28]
	OC	downregulated	tissue	adjacent non-neoplastic tissues from 30 OC patients	OC tissues from 30 OC patients	[27]
	TNBC	downregulated	tissue	para-cancerous tissues	TNBC tissues from 60 TNBC patients	[29]
	TNBC	downregulated	cell	MCF-7	MDA-MB-231	[37]
	BRCA	downregulation	cell	MCF-10A	MCF-7 and T-47D	[38]
	CCa	downregulation	tissue	adjacent normal tissues	CCa tissues from 20 CCa patients	[30]
Bone	SaOS	downregulated	tissue	normal tissues from 10 SaOS patients	SaOS tissues from 10 SaOS patients	[31]
		downregulated	cell	SW1353	U2OS	[31]
		downregulated	tissue	chondroma tissues	SaOS tissues from 12 SaOS patients	[32]
	MM	downregulated	tissue	bone marrow specimens from 21 healthy donors	bone marrow specimens from 36 MM patients	[33]
	CML	downregulated	plasma	plasma from 42 patients respond to IM	plasma from 66 patients non-respond to IM	[34]

GBM glioblastoma multiforme, LGG low-grade glioma, PTC papillary thyroid carcinoma, NSCLC non-small cell lung cancer, GC gastric cancer, HCC hepatocellular carcinoma, CRC colorectal cancer, PDAC pancreatic ductal adenocarcinoma, CHOL human cholangiocarcinoma, OSCC oral squamous cell carcinoma, PCa prostate cancer, ccRCC clear cell renal cell carcinoma, OC ovarian cancer, TNBC triple-negative breast cancer, CCa cervical cancer, BRCA breast cancer, SaOS osteosarcoma, MM multiple myeloma, CML chronic myeloid leukemia, IM Imatinib

Back to article page

ISSN: 2050-7771

Contact us

General enquiries: journalsubmissions@springernature.com